![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Variables Associated With Neuropsychiatric Symptoms in PLWH Receiving Dolutegravir-Based Therapy in Phase III Clinical Trials
|
|
|
Reported by Jules Levin
22nd International AIDS Conference, Amsterdam, Netherlands, July 23-27, 2018
Jean van Wyk,1James Oyee,2Sophie Barthel,2Justin Koteff,3Brian Wynne,3Lloyd Curtis,2Vani Vannappagari,3Nassrin Payvandi,1Val Carr,1Tia Vincent,1Michael Aboud1
1ViiV Healthcare, Brentford, UK; 2GlaxoSmithKline, Stockley Park, UK; 3ViiV Healthcare, Research Triangle Park, NC, USA
![0725181](../images%20/072518/072518-3/0725181.gif)
![0725182](../images%20/072518/072518-3/0725182.gif)
![0725183](../images%20/072518/072518-3/0725183.gif)
![0725184](../images%20/072518/072518-3/0725184.gif)
![0725185](../images%20/072518/072518-3/0725185.gif)
![0725186](../images%20/072518/072518-3/0725186.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|